Table 2.
Clinical and demographic characteristics of low-dose-rate and high-dose-rate brachytherapy patients
| Patient characteristic | Low-dose-rate (n = 51) | High-dose-rate (n = 71) | P-value∗ |
|---|---|---|---|
| Mean age, years (SD) | 65.1 (6.4) | 66.4 (5.5) | .25† |
| Mean prostate gland size, mL (SD) | 34.2 (10.2) | 37.6 (14.5) | .14† |
| T stage | .15‡ | ||
| 1b | 1 (2.0) | 0 (0.0) | |
| 1c | 44 (86.3) | 54 (76.6) | |
| 2a | 6 (11.8) | 16 (23.0) | |
| 2c | 0 (0.0) | 1 (1.0) | |
| Gleason score | <.001 | ||
| 6 | 31 (60.8) | 34 (34.0) | |
| 7 | 20 (39.2) | 39 (55.0) | |
| 8-10 | 0 (0.0) | 8 (11.0) | |
| NCCN risk group | <.001 | ||
| Low risk | 25 (49.0) | 17 (24.0) | |
| Intermediate risk | 25 (49.0) | 41 (58.0) | |
| High risk | 1 (2.0) | 13 (18.0) | |
| Mean pre-treatment PSA (Median, IQR) | 5.80 (4.30-7.79) | 7.67 (5.59-11.00) | .002 |
| Setting | .02§ | ||
| Monotherapy | 46 (90%) | 50 (70%) | |
| Boost | 5 (10%) | 21 (30%) |
Abbreviations: IQR = interquartile range; NCCN = National Comprehensive Cancer Network; PSA = prostate-specific antigen; SD = standard deviation.
∗
Wilcoxon rank sum test.
†
Two sample t test.
‡
Fisher's exact test.
§
χ2 test.